Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s patents for its COVID-19 vaccine technology. The final written decisions remain sealed. U.S. Patent Nos. 10,933,127 (IPR2023-01359) and 10,702,600 (IPR2023-01358) are both titled “Betacoronavirus Mrna Vaccine.” Moderna competitors Pfizer and BioNTech filed two petitions for inter partes review (IPR) in August 2023 against certain claims of each of the patents, accusing Moderna of attempting “to coopt an entire field of mRNA technology.”
Recent Posts
- IP Innovators – From Patent Office to Managing Partner: Chris Agrawal’s Journey
- In Sonos v. Google, the Federal Circuit Has a Chance to Fix Its Prosecution Laches Doctrine
- Perspectives on the PTAB’s 70% All Claims Invalidation Rate
- Moratorium on State AI Regulation Scrapped in Senate Version of Trump’s ‘Big Beautiful Bill’
- Increasing Volume of Patent Deals Could Signal Bounce in Patent Marketplace | IPWatchdog Unleashed